Find your path to Kan
27 people in our graph share verified history with Kan — schools, employers, funds. One of them is your warm intro.
About
Kan Chen is a scientist-turned-investor who leads biotech investments as a Partner and co-lead of healthcare at Qiming Venture Partners. Before joining Qiming in 2016, he spent about 12 years in academic and industry roles, including at the Cleveland Clinic, Harvard Medical School, Johnson & Johnson, and Jiangsu Hengrui Medicine, with expertise across cardiovascular disease, immunology, and cancer. During his academic career he published six papers cited around 900 times, and in industry he contributed to the development of the cancer therapy Camrelizumab, later approved by China's NMPA. At Qiming he has sourced over 30 deals and serves on the boards of more than 20 portfolio companies. His portfolio includes Insilico Medicine, LaNova Medicines, MediLink Therapeutics, Structure Therapeutics, and Abbisko. He earned a PhD in cell biology through a joint Cleveland Clinic and Case Western Reserve University program, completed postdoctoral training in immunology, and holds a bachelor's degree from Fudan University.
Beyond investing
- Education
- Studied at Case Western Reserve University (PhD, Cell Biology) Studied at Harvard Medical School (Postdoctoral training, Immunology) Studied at Fudan University (Bachelor's, Biological Sciences) Studied at Brigham and Women's Hospital (Postdoctoral training, Immunology)
- Awards
- Kan Chen received the Young Investigator Award from the International Society on Thrombosis and Haemostasis. Kan Chen received an American Heart Association Fellowship. Kan Chen received the Cleveland Clinic Foundation's Elsa Albrecht Award. Kan Chen was honored with a Scientific Excellence Award in 2014 during his time at Johnson & Johnson's China R&D division.
- More
- Kan Chen published six papers during his academic career that garnered around 900 citations. Kan Chen played a pivotal role in the development of Camrelizumab, a cancer treatment approved by China's NMPA with annual sales exceeding $500 million.
From published sources — common ground for a warm intro.
Investments
Board seats
Insilico MedicineLaNova MedicinesMediLink Therapeutics
Investor
AbbiskoAllorion TxCandid TxGlubioLaNova MedicineMedilinkStructure Therapeutics
Per curated public sources.
Colleagues at Qiming Venture Partners
Frequently asked questions
- Who is Kan Chen?
- Kan Chen is a scientist-turned-investor who leads biotech investments as a Partner and co-lead of healthcare at Qiming Venture Partners. Before joining Qiming in 2016, he spent about 12 years in academic and industry roles, including at the Cleveland Clinic, Harvard Medical School, Johnson & Johnson, and Jiangsu Hengrui Medicine, with expertise across cardiovascular disease, immunology, and cancer. During his academic career he published six papers cited around 900 times, and in industry he contributed to the development of the cancer therapy Camrelizumab, later approved by China's NMPA. At Qiming he has sourced over 30 deals and serves on the boards of more than 20 portfolio companies. His portfolio includes Insilico Medicine, LaNova Medicines, MediLink Therapeutics, Structure Therapeutics, and Abbisko. He earned a PhD in cell biology through a joint Cleveland Clinic and Case Western Reserve University program, completed postdoctoral training in immunology, and holds a bachelor's degree from Fudan University.
- Where does Kan Chen work?
- Kan Chen is General Partner at Qiming Venture Partners.
- What boards does Kan Chen sit on?
- Kan Chen holds tracked board seats at Insilico Medicine, LaNova Medicines, MediLink Therapeutics.
- What companies has Kan Chen invested in?
- Investments tracked here include Abbisko, Allorion Tx, Candid Tx, Glubio, LaNova Medicine, Medilink, Structure Therapeutics.
- What awards has Kan Chen received?
- Kan Chen received the Young Investigator Award from the International Society on Thrombosis and Haemostasis. Kan Chen received an American Heart Association Fellowship. Kan Chen received the Cleveland Clinic Foundation's Elsa Albrecht Award. Kan Chen was honored with a Scientific Excellence Award in 2014 during his time at Johnson & Johnson's China R&D division.